The use of 15 headache days/month as a threshold to distinguish episodic and chronic migraine does not capture the burden of illness.
Sleep disorders seem to be highly prevalent among children with migraine and are associated with higher headache severity.
Researchers investigated the effect of alpha-lipoic acid (ALA) on oxidative, inflammatory, and mood conditions in women with episodic migraine.
In a randomized, placebo-controlled crossover study, researchers determined the effect of a 2-hour vasoactive intestinal polypeptide infusion on risk for migraine attacks.
Patients treated with gammaCore experienced clinically meaningful benefits.
The FDA has accepted the NDA for AXS-07 for the acute treatment of migraine.
The primary efficacy endpoint was the change in the mean number of migraine days per month during the 12-week study period.
A high-quality diet is associated with lower migraine severity and frequency.
The approval is supported by data from the phase 3 STOP 301 study, which evaluated the safety and tolerability of Trudhesa in 354 adults with migraine.
Patients with chronic migraine and overlapping pain have worse pain-related physical function.